Tag: Multiple Myeloma
Care at High-Volume Facility May Cut Mortality in Multiple Myeloma
Mortality did not differ for those treated by NCICCC MM specialists, highest-volume community oncologists
Salvage Therapy Does Not Up Survival for Progressive Myeloma
Deepening of response through salvage therapy not linked to improved progression-free, overall survival
Novel Therapy Treats Triple-Class Refractory Multiple Myeloma
Partial response or better observed in 26 percent of patients receiving oral selinexor-dexamethasone
Patient Preferences Explored in Multiple Myeloma Treatment
All-oral regimen linked to higher satisfaction with treatment convenience in relapsed, refractory MM
SAVED Score Can Predict Risk for VTE in Multiple Myeloma
Score outperforms current NCCN guidelines for MM patients receiving immunomodulatory therapy
Cost Burden of Disease Progression High in Multiple Myeloma
For patients receiving drug therapy, economic burden substantial across lines of therapy
Hematological Malignancy Risk Up for First-Degree Relatives
Increased familial relative risks for the same tumor type for most hematological malignancies
New Score Predicts Risk for VTE in Those With Multiple Myeloma
New IMPEDE VTE score outperforms International Myeloma Working Group/NCCN guidelines
MGUS Can Progress to Multiple Myeloma Within Five Years
Risk factors associated with progression include IgA isotype, 15 g/L or more monoclonal spike
Depression at Time of Diagnosis May Worsen Survival in Blood Cancers
Risk for death higher even with depression remission versus never experiencing depression
